4552 On Other Exchanges
4552 is not on other exchanges.

jcr pharmaceuticals co ltd (4552) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for JCR PHARMACEUTICALS CO LTD (4552)

Related News

No related news articles were found.

jcr pharmaceuticals co ltd (4552) Related Businessweek News

No Related Businessweek News Found

jcr pharmaceuticals co ltd (4552) Details

JCR Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of bio therapeutics and regenerative medicines primarily in Japan. The company offers GROWJECT, a recombinant human growth hormone for the treatment of short stature; Epoetin Alfa BS Inj. JCR, a recombinant erythropoietin for the treatment of anemia; and TEMCELL HS Inj, a therapeutic product using mesenchymal stem cells for the treatment of acute graft-versus-host disease. Its product pipeline includes Follicle stimulating hormone, which is in Phase I/II clinical trials for the treatment of infertility; BBB-Penetrating Iduronate-2-sulfatase that is in Phase I/II clinical trials for the treatment of hunter syndrome; Alpha-galactosidase A that is in Phase II/III clinical trials to treat fabry disease; Iduronate-2-sulfatase, which is in the clinical trial in preparation stage for hunter syndrome; and Darbopoetin Alfa that is in Phase III clinical trials to treat renal anemia. The company’s preclinical product pipeline comprises Glucocerebrosidase for gaucher disease, BBB-Penetrating acid alpha-glucosidase for pompe disease, and Long-acting Somatropin for growth disorder treatment. It is also developing human mesenchymal stem cells for the treatment of graft-versus-host disease. The company has a co-development and licensing agreement with Teijin Limited to develop allogeneic regenerative medical product using dental pulp stem cells. JCR Pharmaceuticals Co., Ltd. was founded in 1975 and is headquartered in Ashiya, Japan.

566 Employees
Last Reported Date: 06/28/17
Founded in 1975

jcr pharmaceuticals co ltd (4552) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jcr pharmaceuticals co ltd
Sumitomo Dainippon Pharma Co., Ltd. and JCR Pharmaceuticals Co., Ltd. Sign a License Agreement on Blood-Brain Barrier Penetration Technology for Creation of Therapeutic Agent for Central Nervous System Diseases

JCR Pharmaceuticals Co., Ltd. and JCR Pharmaceuticals Co., Ltd. announced on February 26, 2018, the two companies have signed a license agreement on rights possessed by JCR concerning a substance created by applying JCR's J-Brain Cargo® blood-brain barrier (BBB) penetration technology to a candidate compound of Sumitomo Dainippon Pharma's choice (hereinafter referred to as the "Substance"), and whose rights are shared by both companies, following an agreement on development of the Substance as a therapeutic agent for specified central nervous system diseases by Sumitomo Dainippon Pharma. Under the license agreement with JCR, Sumitomo Dainippon Pharma retains the exclusive rights to research, develop, and market the Substance indicated for specified central nervous system diseases in Japan and North America, in return for which Sumitomo Dainippon Pharma will provide up to 3.7 billion in total to JCR including an upfront payment and development milestone payments at each development phase. Following the commercial launch of the Substance, Sumitomo Dainippon Pharma will also pay royalties in accordance with the sales amount and milestone payments on sales to JCR that will be calculated on the basis of sales target achievements. Sumitomo Dainippon Pharma has also option rights to additional indications and territory (China). Sumitomo Dainippon Pharma expects that the Substance will become an innovative therapeutic agent in the central nervous system area, which has high unmet medical needs. JCR has conducted Phase I and Phase II clinical studies of JR-141, a J-Brain Cargo®-applied enzyme preparation for treatment of Hunter syndrome, and has obtained positive results. Aside from those in-house programs on J-Brain Cargo® platform, this is JCR's first license agreement on a candidate drug using J-Brain Cargo®.

JCR Pharmaceuticals Co., Ltd. Presents at 14th Annual World Symposium, Feb-07-2018 03:15 PM

JCR Pharmaceuticals Co., Ltd. Presents at 14th Annual World Symposium, Feb-07-2018 03:15 PM. Venue: Manchester Grand Hyatt, 1 Market Place, San Diego, California, United States. Speakers: Hiroyuki Sonoda.

Kissei Pharmaceutical Co., Ltd. and JCR Pharmaceuticals Co., Ltd. Announce Positive Results of the Phase III Study for JR-131

Kissei Pharmaceutical Co., Ltd. and JCR Pharmaceuticals Co., Ltd. jointly announced positive results of the phase III study for JR-131, a proposed biosimilar to darbepoetin alfa, a long-acting erythropoiesis-stimulating agent for the treatment of renal anemia. In the Phase III study initiated in August 2016, JR-131 demonstrated equivalence in efficacy and safety compared with darbepoetin. Accordingly, in a primary endpoint of efficacy, the equivalence was verified for variations in hemoglobin concentration and the similarity with regard to the safety profile was confirmed. Kissei and JCR concluded a collaborative research and development agreement for JR-131 in September 2013, and have been advancing the development with the aim to apply for marketing approval in 2018. JR-131 which offers economic efficiency can become a new treatment option in the renal diseases areas. Both companies are aiming to contribute to healthcare through the development of JR-131, by leveraging JCR's strong know-how and expertise in biopharmaceutical manufacturing that meets the global quality standards, and Kissei's outstanding performance in the renal diseases including dialysis areas and sales results of the first biosimilar in Japan, "Epoetin alfa BS Injection [JCR]".


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4552 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4552.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4552 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact JCR PHARMACEUTICALS CO LTD, please visit www.jcrpharm.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.